Achieving Clinical Success with Safe & Efficacious TGF-B Therapies

The race for clinical approval of TGF-β therapies is heating up, fueled by significant investments like Corbus Pharmaceuticals’ recent $98.5 million and Biacara Therapeutics’ $165 million funding rounds. These substantial investments are driving their TGF-β therapies into clinical trials, paving the way for biopharma companies to achieve commercial success.

With this in mind, the TGF-B Targeted Drug Development Summit is one you won’t want to miss, spotlighting innovative ways large pharma companies such as Amgen, Genentech, and Pfizer are overcoming toxicity, translation, and proving clinical efficacy.

You can take advantage of the 6+ hours of interactive networking to learn from other’s work in the space as well as our Pre-Conference Workshop Day including two sessions:

Morning session: Designing the Most Effective Clinical Trials for TGF-β Targeted Therapies Toward Clinical Efficacy

Afternoon session: Avoiding the Pitfalls in Targeting TGF-β to Achieve Better Specificity, Reduced Toxicity & More Effective Treatments

Download a copy of the event guide here to discover more about our speakers and sessions!

We also have additional savings and group discounts on offer, our online booking system is live here!